


The Critical Role of Advanced Practice Providers in Optimizing Care for Patients With Multiple Myeloma



The following research was commissioned by Janssen Oncology and the Advanced Practitioner Society for Hematology and Oncology (APSHO) through The Harris Poll among 200 APPs who see patients with multiple myeloma and 100 multiple myeloma patients in the United States.


Multiple myeloma (MM) is a rare, incurable cancer

that affects a type of white blood cell called plasma cells, which are found in the bone marrow.^{1,2,3}



~36K people are diagnosed with multiple myeloma each year.⁴
~13K people die from the disease each year.⁴


For most multiple myeloma patients, the length of remission decreases with each new relapse, and depth and duration of response to treatment is greater in the first lines of therapy, making early diagnosis and first-line treatment decisions critical to prognosis.⁵



The role of Advanced Practice Providers (APPs) on a multiple myeloma treatment team

APPs are a category of mid-level healthcare practitioners with advanced degrees, such as nurse practitioners and physician assistants.

In their role, they work closely with the full cancer treatment team, including the oncologist, to provide surveillance and management of disease symptoms, and with patients to help them understand and navigate their treatment journeys.



The relationship between a multiple myeloma patient and their Advanced Practice Provider (APP) is central to how they experience their multiple myeloma treatment journey.

38% of patients with multiple myeloma **had never heard of the disease** prior to being diagnosed.⁶

93% of patients with an APP agree **that APPs are essential** to their multiple myeloma care.^{*6}

61% of patients **feel like they could ask APPs questions** they could not ask a doctor/oncologist.⁶



Despite the value that APPs bring to their patient's care, **36% of multiple myeloma patients have never heard the term Advanced Practice Provider (APP)** - a knowledge gap that may prevent patients from accessing the support they need.⁶

APPs want to be more involved with patient care, both at diagnosis and throughout duration of therapy, but are faced with challenges.

More than 4 in 5 APPs feel health disparities exacerbate issues in providing adequate care to MM patients.⁶



Diagnosis represents a pivotal moment to build a strong relationship with a patient and their care team. **91% of APPs feel being more involved in a patient's disease management at the time of diagnosis** would help them better manage the patient's overall treatment journey to provide the best care possible.⁶



APPs see first-line treatment as critical, and **78% wish they could be more involved in patient management at initial diagnosis.**⁶

However, the majority of APPs feel they are prevented from being more involved in their patient's first line of treatment due to factors like time constraints, the patient preferring the oncologist be more involved, or the oncologist taking the lead at the appointment.⁶

94% of APPs want more educational resources specific to MM.⁶

72% of APPs felt knowledgeable about multiple myeloma before treating their first patient – yet a strong majority still desire more information and tailored, credible resources to turn to.⁶

76% of APPs feel various resources and education would help them optimize the care they provide to multiple myeloma patients.⁶

Resources APPs desire greater access to

Professional conferences (**51%**)⁶

Formal trainings (**48%**)⁶

Medical information websites solely dedicated to multiple myeloma (**37%**)⁶

In response to these data, Janssen Oncology, in partnership with the Advanced Practitioner Society for Hematology and Oncology (APSHO), launched Make It HAPPen™, a national campaign that is raising awareness of APPs as critical stakeholders in optimizing care for people living with multiple myeloma.

*Small base (<100) results to be interpreted with caution.

1. Cancer Stats: Myeloma. National Cancer Institute: Surveillance, Epidemiology, and End Results Program. Accessed August 17, 2023. <https://seer.cancer.gov/statfacts/html/mulmy.html>

2. Learn More About Multiple Myeloma. The Multiple Myeloma Research Foundation. Accessed August 17, 2023. <https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html>

3. What is Multiple Myeloma? The Multiple Myeloma Research Foundation. Accessed August 17, 2023. <https://themmrff.org/multiple-myeloma/>

4. American Cancer Society. Key statistics about myeloma. Accessed August 17, 2023. <https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html>

5. Fonseca R, Usmani SZ, Mehra M, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. *BMC Cancer*. 2020;20(1). doi:10.1186/s12885-020-07503-y

6. Janssen Oncology & The Advanced Practitioner Society for Hematology & Oncology. About the Survey: This survey was conducted online within the United States by The Harris Poll on behalf of Janssen Oncology & APShO, from May 15-June 9, 2023, among 100 US adults ages 18 and older who have been diagnosed with multiple myeloma and 200 APPs (nurse practitioners [NPs] [n=131] and physician assistants [PAs] [n=69]) who see at least 3 patients with multiple myeloma annually.

MAKE IT HAPPEN™

To Better Serve the Multiple Myeloma Community